Verici Dx PLC ISO 27001 Information Security Certification
November 29 2023 - 1:00AM
RNS Non-Regulatory
TIDMVRCI
Verici Dx PLC
29 November 2023
Verici Dx plc
("Verici Dx" or the "Company")
ISO 27001 Information Security Certification Achieved
Verici Dx, a developer of advanced clinical diagnostics for
organ transplant, announces that it has attained the ISO 27001
certification for its Information Security Management System
("ISMS").
ISO 27001 is an international standard specifying requirements
for an ISMS, and conformity with the standard means that Verici
Dx's system meets world-wide best practice with regards to managing
risks related to the security of data owned or handled by the
Company.
This certification underlines Verici Dx's commitment to
implementing comprehensive security measures, ensuring the
protection of sensitive data and information, and reinforces the
Company's position as a trusted partner in industry and within
patient care. With this certification, Verici Dx is well-equipped
to continue delivering innovative diagnostic solutions while
ensuring the highest level of protection for all sensitive
information.
Dave Schultenover, VP Quality and Regulatory Affairs at Verici
Dx, said: "We are pleased to have achieved the ISO 27001
certification, which underscores our unwavering commitment to
maintaining the utmost security and confidentiality of data within
our operations."
Patti Connolly, Chief Operating Officer at Verici Dx, added: "
Achieving this international standard is testament to the quality
of the Verici Dx team, and the robustness of our systems and
processes that maintain the highest level of data protection for
patients, clients, partners, and stakeholders."
Enquiries:
Verici Dx www.v ericidx .com
Sara Barrington, CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Tel: 020 7496 3000
Adviser & Broker)
Aubrey Powell / Sam Butcher / Jalini
Kalaravy
Walbrook PR Limited Tel: 020 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Stephanie Cuthbert / Mob: 07980 541 893 / 07502 558 258
Sam Allen
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of
leading-edge tests forming a kidney transplant platform for
personalised patient and organ response risk to assist clinicians
in medical management for improved patient outcomes. The underlying
technology is based upon artificial intelligence assisted
transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for
transplant prognosis of risk of injury, rejection and graft failure
from pre-transplant to late stage. The Company also has a mission
to accelerate the pace of innovation by research using the fully
characterised data from the underlying technology, including
through collaboration with medical device, biopharmaceutical and
data science partners.
The foundational research was driven by a deep understanding of
cell-mediated immunity and is enabled by access to expertly curated
collaborative studies in highly informative cohorts in kidney
transplant.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAMZMZMZRNGFZZ
(END) Dow Jones Newswires
November 29, 2023 02:00 ET (07:00 GMT)
Verici Dx (LSE:VRCI)
Historical Stock Chart
From Dec 2024 to Jan 2025
Verici Dx (LSE:VRCI)
Historical Stock Chart
From Jan 2024 to Jan 2025